Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-case experimental study of oxytocin for addiction severity in a patient with oropharyngeal squamous cell carcinoma
TCTR20180511003Phase 1Terminated
- Start
- Jun 2014
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxytocin in oropharyngeal squamous cell carcinoma (OPSCC) and substance use disorder (SUD), sponsored by none. Primary endpoint: Addiction Severity Index score change. Started Jun 2014; status: terminated.
02
Drugs
oxytocin
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)substance use disorder (SUD)
Beyond the preview
Go deeper on TCTR20180511003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180511003.